Oncology Position

Quote
AZ’s division, ZS, was formed 1Q 2016. The drug they were hired to sell is still not approved and it has been OVER 2 years. They were assigned to other drugs, still paid base and bonus and stock keeps vesting. R-E-L-A-X.
 


















Why would they put together this team? We seem to keep shooting for the moon. Remember the launch of Praluent? All of those people have/will leave. And Eylea keeps paying for all of you.
 






eyelea goes away in 2020 so this is foundation for transition, as far as the whiner who “wants to be in oncology” give me a break. You’re a drug rep. Asthma, antibiotics, blood pressure....what’s the difference?! Oh...buy and bill is such a mystery?! Please.
 
























Sanofi stumbles...

From the Sanofi press release.
  • In March, the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application for cemiplimab (collaboration with Regeneron) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery.
NO mention of BLA or FDA for cemiplimab. Something is bad wrong here.
 






anonymous said:
Sanofi stumbles...

From the Sanofi press release.
  • In March, the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application for cemiplimab (collaboration with Regeneron) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery.
NO mention of BLA or FDA for cemiplimab. Something is bad wrong here I'm a ho mo too.
Click to expand...
 
















































Now we're getting somewhere. Approval by end of July leaves 5 months remaining in the year. Can probably sell $1M by year-end, might get lucky and hit $1.25 but that's a stretch. Everyone has to chip in and get a patient.
 


















Top Bottom
Back
Quote